Skip to main content
Industry News
FDA approves Keytruda plus chemo for advanced cancer

Merck's Keytruda, or pembrolizumab, used with chemotherapy was approved by the FDA to treat metastatic or locally advanced esophageal and gastroesophageal junction cancer in certain patients. The approval was based on a clinical trial that found the combination reduced the risk of disease progression or death by 35%.

Full Story: